Search

Merck & Co Inc.

Lezárt

SzektorEgészségügy

144.86 0.78

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

143.4

Maximum

144.94

Fő mutatók

By Trading Economics

Bevétel

2.9B

-1.3B

Értékesítés

321M

17B

P/E

Szektor átlag

115.88

56.432

Egy részvényre jutó nyereség

-0.13

Osztalékhozam

2.31

Profit margin

-8.051

Munkavállalók

73,000

EBITDA

3.4B

1.4B

Ajánlások

By TipRanks

Ajánlások

Vétel

12 hónapos előrejelzés

+11.61% upside

Osztalékok

By Acuity

Osztalékhozam

Szektor átlag

2.31%

2.27%

Következő eredményjelentés

2026. okt. 29.

Következő osztalékfizetési dátum

2026. okt. 7.

Következő korábbi osztalék dátum

2026. dec. 14.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

50B

357B

Előző nyitás

144.08

Előző zárás

144.86

Hangulat hírek alapján

By Acuity

37%

63%

75 / 339 Rangsor szerint Healthcare

Merck & Co Inc. Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. szept. 16. 23:51 UTC

Merck & Co Inc is advancing in after-market trading, supported by positive U.S. retail sales data, despite ongoing concerns over TIC flows and Treasury yields.

2026. szept. 15. 23:01 UTC

Merck & Co Inc shares are lower in after-market hours. Broader market sentiment is impacted by a significant decline in the New York Empire State Manufacturing Index.

2026. szept. 14. 23:06 UTC

Merck & Co Inc shares rose in after-market trading following Monday's close, despite earlier declines and no specific news to explain the movement.

2026. szept. 11. 19:36 UTC

Merck & Co Inc shares are declining amid broader market trends following inflation data that heightened interest rate hike speculation. No specific company news was identified.

2026. szept. 10. 20:07 UTC

News

Merck & Co Inc shares are lower today despite HSBC raising its price target to $172 and noting insider buying activity.

2026. szept. 9. 19:36 UTC

News

Merck & Co. shares are lower after a court upheld Medicare's drug-price negotiations, raising concerns about future prescription drug spending.

2026. szept. 8. 23:06 UTC

News

Merck & Co. shares are higher after Karim Mikhail's appointment to lead the FDA's Center for Biologics Evaluation and Research, boosting the company's regulatory reputation.

2026. szept. 4. 23:05 UTC

Merck & Co Inc shares are higher in after-market trading, despite no specific news. Broader market signals show mixed economic indicators and rising Treasury yields.

2026. szept. 3. 23:05 UTC

Merck & Co Inc shares are lower in after-market hours, reflecting a slight decline since Thursday's close amid broader market gains.

2026. szept. 2. 19:46 UTC

Social Media
News

Merck & Co Inc is rising following positive results from the ATLAS-UC Phase 3 trial, which met its primary endpoint of clinical significance.

2026. szept. 1. 23:07 UTC

Merck & Co Inc. shares were roughly flat during after-market hours, with no specific company news identified amid broader market fluctuations driven by rising oil prices.

2026. aug. 31. 23:16 UTC

Merck & Co Inc shares are trading higher in after-market hours. Broader market sentiment is influenced by escalating geopolitical tensions and inflation concerns.

2026. aug. 28. 23:01 UTC

Merck & Co Inc shares are higher in after-market trading, supported by rising Treasury yields and trading above their 20-day moving average.

2026. aug. 27. 23:01 UTC

Merck & Co Inc. shares are higher in after-market trading, reflecting routine performance despite three consecutive lower sessions. The stock remains above its 20-day moving average.

2026. aug. 26. 23:11 UTC

Merck & Co Inc is higher in after-market hours, reflecting broader market gains. The stock remains above its 20-day moving average.

2026. aug. 25. 23:06 UTC

Social Media

Merck & Co Inc reached all-time highs in after-market trading, gaining over $6 amid positive social media sentiment and broader market dynamics.

2026. aug. 24. 23:16 UTC

Merck & Co Inc shares are higher in after-market trading, showing stable performance since Monday's close. The stock remains above its 20-day moving average.

2026. aug. 21. 19:31 UTC

News
Social Media

Merck & Co Inc shares are higher today as Goldman Sachs and Morgan Stanley upgraded their ratings and raised price targets, citing confidence in cancer treatments.

2026. aug. 20. 19:31 UTC

News
Social Media
Event

Merck & Co Inc shares are lower today following downgrades from RBC Capital and UBS, with both firms setting a price target of $150.

2026. aug. 19. 23:41 UTC

Event
Social Media

Merck & Co Inc shares declined in after-market trading despite positive Phase 3 trial results for its mRNA-based therapy combined with KEYTRUDA.

2026. aug. 17. 19:36 UTC

News

Merck & Co Inc shares are higher during Monday's session, reflecting a slight cumulative return since Friday's close amid rising long-term Treasury yields.

2026. aug. 15. 00:01 UTC

Merck & Co Inc shares are lower in after-market hours following notable volatility during the session, despite mixed global market performance.

2026. aug. 14. 23:21 UTC

Merck & Co Inc shares are lower in after-market trading following a decline in U.S. retail sales for July, raising concerns about consumer demand.

2026. aug. 13. 23:06 UTC

Merck & Co Inc. shares were roughly flat in after-market hours, remaining above their 20-day moving average after three consecutive sessions of higher finishes.

2026. aug. 12. 19:56 UTC

News

Daiwa Capital upgraded Merck to Outperform, raising the price target to $143. The stock remains higher since Tuesday's close amid positive FDA news.

2026. aug. 11. 19:36 UTC

News

Merck & Co. shares are lower today despite Argus Research maintaining a Buy rating and raising the price target to $145.

2026. aug. 10. 19:36 UTC

Social Media
News

Merck & Co Inc disclosed a $3.76 million stake in Evaxion Biotech, boosting shares higher amid positive sentiment and strong options trading ahead of earnings.

2026. aug. 7. 22:06 UTC

Merck & Co Inc. shares were roughly flat in after-market hours. This stability aligns with broader positive sentiment on Wall Street amid easing interest rate concerns.

2026. aug. 6. 23:01 UTC

Event

Merck & Co Inc shares are trading lower in after-market hours following the FDA's acceptance of a supplemental application for ENFLONSIA™.

2026. aug. 5. 19:43 UTC

News
Social Media

Merck & Co. received Health Canada approval for Keytruda, yet shares are lower amid mixed market sentiment following disappointing ADP employment data.

Társak összehasonlítása

Árváltozás

Merck & Co Inc. Előrejelzés

Célár

By TipRanks

11.61% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 160.489 USD  11.61%

Magas 180 USD

Alacsony 105 USD

19 Wall Street elemző 12 hónapos célárain alapulva a(z)Merck & Co Inc. termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Vétel

19 ratings

14

Vétel

5

Tartás

0

Eladás

Hangulat

By Acuity

75 / 339 Rangsor szerint Egészségügy

Hangulat hírek alapján

Bullish bizonyíték

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag alatti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
help-icon Live chat